An overview of current and future treatment options for patients with cytomegalovirus retinitis

Bibliography

• Stadler LP, Bernstein DI, Callahan ST, et al. Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males. Clin Infect Dis 2010;51(10):e76-81
   PubMed Web of Science ®Google Scholar
• Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992;14:608-15
   PubMed Web of Science ®Google Scholar
• Fiala M, Carson S, Poolsawat S, et al. Cytomegalovirus retinitis secondary to chronic viremia in phagocytic leukocytes. Am J Ophthalmol 1977;84:567-73
   PubMed Web of Science ®Google Scholar
• Glasgow BJ, Weisberger AK. A quantitative and cartographic study of retinal microvasculopathy in acquired immunodeficiency syndrome. Am J Ophthalmol 1994;118:46-56
   PubMed Web of Science ®Google Scholar
• Shepp DH, Moses JE, Kaplan MH. Seroepidemiology of cytomegalovirus in patients with advanced HIV disease: influence on disease expression and survival. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:460-8
   PubMedGoogle Scholar
• Saillour F, Bernard N, Dequae-Merchadou L, et al. Predictive factors of occurrence of cytomegalovirus disease and impact on survival in the Aquitaine Cohort in France, 1985 to 1994. Groupe d’Epidémiologie Clinique du SIDA en Aquitaine. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:171-8
   PubMedGoogle Scholar
• Hoover DR, Peng Y, Saah A, et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 1996;114:821-7
   PubMed Web of Science ®Google Scholar
• Jabs DA, Van Natta ML, Kempen JH, et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2002;133:48-61
   PubMed Web of Science ®Google Scholar
• Kuo IC, Kempen JH, Dunn JP, et al. Clinical characteristics and outcomes of cytomegalovirus retinitis in persons without human immunodeficiency virus infection. Am J Ophthalmol 2004;138:338-46
   PubMed Web of Science ®Google Scholar
• Wagle AM, Biswas J, Gopal L, Madhavan JN. Clinical profile and immunological status of CMV retinitis in organ transplant recipients. Indian J Ophthalmol 2002;50:115-21
   PubMedGoogle Scholar
• Ng P, McCluskey P, McCaughan G, et al. Ocular complications of heart, lung, and liver transplantation. Br J Ophthamol 1993;116:713-20
   Google Scholar
• Assi AC, Lightman S. Cytomegalovirus retinitis in patients with Good syndrome. Arch Ophthalmol 2002;120:501-12
   Google Scholar
• Vertes D, Snyers B, De Potter P. Cytomegalovirus retinitis after low-dose intravitreous triamcinolone acetonide in an immunocompetent patient: a warning for the widespread use of intravitreous corticosteroids. Int Ophthalmol 2010;30:595-7
   PubMedGoogle Scholar
• Saidel MA, Berreen J, Margolis TP. Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol 2005;140:1141-3
   PubMed Web of Science ®Google Scholar
• Ufret-Vincenty RL, Singh RP, Lowder CY, Kaiser PK. Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. Am J Ophthalmol 2007;143:334-5
   PubMed Web of Science ®Google Scholar
• Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 2008;145:397-408
   PubMed Web of Science ®Google Scholar
• Jabs DA. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome- bench to bedside. LXVII Edward Jackson Memoral Lecture. Am J Ophthalmol 2011;151:198-216
   PubMed Web of Science ®Google Scholar
• Jabs DA, Enger C, Dunn JP, for the Cytomegalovirus Retinitis and Viral Resistance Research Group. Cytomegalovirus retinitis and viral resistance. 3. Culture results. Am J Ophthalmol 1998;126:543-9
   PubMed Web of Science ®Google Scholar
• Jabs DA, Martin BK, Forman MS, et al. Cytomegalovirus (CMV) blood DNA load, CMV retinitis progression, and occurrence of resistant CMV in patients with CMV retinitis. J Infect Dis 2005;192:640-9
   PubMed Web of Science ®Google Scholar
• Hu H, Jabs DA, Forman MS, et al. Comparison of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitis. J Infect Dis 2002;185:861-7
   PubMed Web of Science ®Google Scholar
• Duryea E, Sanchez P, Sheffield J, et al. Maternal human immunodeficiency virus infection and congenital transmission of cytomegalovirus. Pediatr Infect Dis J 2010;29:915-18
   PubMed Web of Science ®Google Scholar
• Yinon Y, Farine D, Yudin M. Screening, diagnosis, and management of cytomegalovirus infection in pregnancy. Obstet Gynecol Surv 2010;65:736-43
   PubMed Web of Science ®Google Scholar
• Ghekiere S, Allegaert K, Cossey V, et al. Ophthalmological findings in congenital cytomegalovirus infection: when to screen, when to treat? J Pediatr Ophthalmol Strabismus 2012;49:274-82
   PubMed Web of Science ®Google Scholar
• Mets M, Chhabra M. Eye manifestations of intrauterine infections and their impact on childhood blindness. Surv Ophthalmol 2008;53:95-111
   PubMed Web of Science ®Google Scholar
• Coats K, Demmler G, Paysse E, et al. Ophthalmological findings in children with congenital cytomegalovirus infection. J AAPOS 2000;4:110-16
   PubMed Web of Science ®Google Scholar
• Boppana S, Amos C, Britt W, et al. Late onset and reactivation of chorioretinitis in children with congenital cytomegalovirus infection. Pediatr Infect Dis J 1994;13:1139-42
   PubMed Web of Science ®Google Scholar
• Biron KK. Antiviral drugs for cytomegalovirus diseases. Antivir Res 2006;71:154-63
   PubMed Web of Science ®Google Scholar
• Sarmiento E, Lanio N, Gallego A, et al. Immune monitoring of anti-cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int Immunopharmacol 2009;9:649-52
   PubMed Web of Science ®Google Scholar
• Al-Hajjar S, Al Seraihi A, Al Muhsen S, et al. Cytomegalovirus infections in unrelated cord blood transplantation in pediatric patients: incidence, risk factors, and outcomes. Hematol Oncol Stem Cell Ther 2011;4:67-72
   PubMedGoogle Scholar
• Avery RK. Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients. Curr Opin Cardiol 1998;13:122-9
   PubMed Web of Science ®Google Scholar
• Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Crippa F, Corey L, Chuang EL, et al. Virological, clinical, and ophthalmological features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. Clin Inf Dis 2001;32:214-19
   PubMed Web of Science ®Google Scholar
• Skolnik PR, Kosloff BR, Hirsch MS. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis 1988;157:508-14
   PubMed Web of Science ®Google Scholar
• Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 1995;93:623-83
   PubMedGoogle Scholar
• Late HIV testing- 34 states, 1996-2005. MMWR Morb Mortal Wekly Rep 2009;58:661-5
   Google Scholar
• Field AK, Davies ME, DeWitt C, et al. 9-([2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci USA 1983;80:4139-43
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med 1988;108:585-94
   PubMed Web of Science ®Google Scholar
• Palestine AG, Plis MA, DeSmet MD, et al. A randomized controlled trial of Foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991;115:665-73
   PubMed Web of Science ®Google Scholar
• Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996;334:1491-7
   PubMed Web of Science ®Google Scholar
• Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9
   PubMed Web of Science ®Google Scholar
• Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997;126:257-63
   PubMed Web of Science ®Google Scholar
• Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002;346:1119-26
   PubMed Web of Science ®Google Scholar
• Teoh SC, Ou X, Lim TH. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen. Ophthalmology 2012;119:588-95
   PubMed Web of Science ®Google Scholar
• Masur H, Whitcup SM, Cartwright C, et al. Advances in the management of AIDS-related cytomegalovirus retinitis. Ann Intern Med 1996;125:126-36
   PubMed Web of Science ®Google Scholar
• Taskintuna I, Rahhal FM, Rao NA, et al. Adverse events and autopsy findings after intravitreous cidofovir (HPMPC) therapy in patients with acquired immune deficiency syndrome (AIDS). Ophthalmology 1997;104:1827-36
   PubMed Web of Science ®Google Scholar
• Jabs DA, Ahuja A, Van Natta M, Studies of the Ocular Complications of AIDS Research Group. Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2013;120:1262-70
   PubMed Web of Science ®Google Scholar
• Vitravene Study Group. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is peprsistently active despite other therapies in patients with AIDS. Am J Ophthalmol 2002;133:475-83
   PubMed Web of Science ®Google Scholar
• Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20
   PubMed Web of Science ®Google Scholar
• Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999;340:1063-70
   PubMed Web of Science ®Google Scholar
• Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology 1994;101:1250-61
   PubMedGoogle Scholar
• Studies of Ocular Complications of AIDS Research Group. The ganciclovir implant plus oral ganciclovir versus parenteral cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: The Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Am J Ophthalmol 2001;131:457-67
   PubMed Web of Science ®Google Scholar
• Kempen JH, Jabs DA, Wilson LA, et al. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis 2003;37:1365-73
   PubMed Web of Science ®Google Scholar
• Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999;282:1633-7
   PubMed Web of Science ®Google Scholar
• Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998;126:817-22
   PubMed Web of Science ®Google Scholar
• Jouan M, Saves M, Tubiana R, et al. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2001;15(1):23-31
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Raboud J, Angel JB, et al. Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. HIV Clin Trials 2006;7:1-9
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Kempen JH, Bolton SG, et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000;129:634-9
   PubMed Web of Science ®Google Scholar
• Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999;179:697-700
   PubMed Web of Science ®Google Scholar
• Robinson MR, Reed G, Csaky KG, et al. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophthalmol 2000;130:49-56
   PubMed Web of Science ®Google Scholar
• Karavellas MP, Song M, Macdonald JC, Freeman WR. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am J Ophthalmol 2000;130:57-64
   PubMed Web of Science ®Google Scholar
• Kempen JH, Min YI, Freeman WR, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology 2006;113:684-94
   PubMed Web of Science ®Google Scholar
• Ortega-Larrocea G, Espinosa E, Eeyes-Teran G. Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patents with delayed highly active antiretroviral therapy. AIDS 2005;19:735-8
   PubMed Web of Science ®Google Scholar
• Zolopa A, Anderson J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009;4:e5575
   PubMed Web of Science ®Google Scholar
• Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs deferred ART during an opportunistic infection. PLoS One 2010;5:e11416
   PubMed Web of Science ®Google Scholar
• Kimberlin D, Lin C, Sanchez J, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143:16-25
   PubMed Web of Science ®Google Scholar
• Amir J, Wolf DG, Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010;169:1061-7
   PubMed Web of Science ®Google Scholar
• del Rosal T, Baquero-Artigao F, Blazquez D, et al. Treatment of symptomatic congenital cytomegalovirus infection beyond the neonatal period. J Clin Virol 2012;55:72-4
   PubMed Web of Science ®Google Scholar
• Tanaka-Kitajima N, Sugaya N, Futatani T, et al. Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatr Infect Dis J 2005;24:782-5
   PubMed Web of Science ®Google Scholar
• Shoji K, Ito N, Ito Y, et al. Is a 6-week course of ganciclovir therapy effective for chorioretinitis in infants with congenital cytomegalovirus infection? J Pediatr 2010;157:331-3
   PubMed Web of Science ®Google Scholar
• Weng Y, Chu S, Lien R, et al. Clinical experience with ganciclovir and anti-cytomegalovirus immunoglobulin treatment for a severe case of congenital cytomegalovirus infection. Chang Gung Med J 2003;26:128-32
   PubMedGoogle Scholar
• Hodson EM, Ladhani M, Webster AC, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013;2:CD003774
   Google Scholar
• Ar MC, Ozbalak M, Tuzuner N, et al. Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. Transplant Proc 2009;41:1648-53
   PubMed Web of Science ®Google Scholar
• Thorne JE, Jabs DA, Vitale S, et al. Catheter complications in AIDS patients treated for cytomegalovirus retinitis. AIDS 1998;12:2321-7
   PubMed Web of Science ®Google Scholar
• Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The ganciclovir Implant Study Group. N Engl J Med 1997;337:83-90
   PubMed Web of Science ®Google Scholar
• Holland GN, Buhles WC Jr, Mastre JJ, Kaplan HJ; Group UCRS. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy: use of a standardized system for the assessment of disease outcome. Arch Ophthalmol 1989;107:1759-66
   PubMed Web of Science ®Google Scholar
• Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 2009;58(RR-4):55
   PubMedGoogle Scholar
• Jacobson MA, O’Connell JJ, Brodie HR, et al. Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol 1988;25:339-49
   PubMed Web of Science ®Google Scholar
• Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010;23:689-712
   PubMed Web of Science ®Google Scholar
• Jabs DA, Enger C, Dunn JP, Forman F; for the Cytomegalovirus Retinitis and Viral Resistance Study Group. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J Infect Dis 1998;177:770-3
   PubMed Web of Science ®Google Scholar
• Kuo IC, Imai Y, Shum C, et al. Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. Am J Ophthalmol 2003;135:20-5
   PubMed Web of Science ®Google Scholar
• Dunn JP, MacCumber MW, Forman MS, et al. Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am J Ophthalmol 1995;119:587-96
   PubMed Web of Science ®Google Scholar
• Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol 1996;114:22-33
   Google Scholar
• Drew WL. Is combination antiviral therapy for CMV superior to monotherapy? J Clin Virol 2006;35:485-8
   PubMed Web of Science ®Google Scholar
• Martin BK, Ricks MO, Forman MS, Jabs DA; Cytomegalovirus Retinitis and Viral Resistance Study Group. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin Infect Dis 2007;44:1001-8
   PubMed Web of Science ®Google Scholar
• Avery RK. Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients. Curr Opin Cardiol 1998;13:122-9
   PubMed Web of Science ®Google Scholar
• Gorensek MJ, Stewart RW, Keys TF, et al. Symptomatic cytomegalovirus infection as a significant risk factor for major infections after cardiac transplantation. J Infect Dis 1988;158:884-7
   PubMed Web of Science ®Google Scholar
• Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995;123:18-26
   PubMed Web of Science ®Google Scholar
• Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010;27:1427-31
   Google Scholar
• Collier A, Chandler SH, Handsfield HH, et al. Identification of multiple strains of cytomegalovirus in homosexual men. J Infect Dis 1989;159:123-6
   PubMed Web of Science ®Google Scholar
• Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010;70:965-81
   PubMed Web of Science ®Google Scholar
• Springer KL, Chou S, Li S, et al. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005;43:208-13
   PubMed Web of Science ®Google Scholar
• The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group.MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. Arch Ophthalmol 1997;115:1528-36
   PubMedGoogle Scholar
• Borucki MJ, Spritzler J, Asmuth DM, et al. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with cytomegalovirus retinitis. Antiviral Res 2004;64:103-11
   PubMed Web of Science ®Google Scholar
• Yamani H, Avery R, Mawhorter S, et al. Hypogammglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (Cytogam®) on infection and rejection outcomes. Transpl Infect Dis 2001;3(Suppl 2):40-3
   PubMedGoogle Scholar
• Kocher AA, Bonaros N, Dunkler D, et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J Heart Lung Transplant 2003;22:250-7
   PubMed Web of Science ®Google Scholar
• Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010;90:419-26
   PubMed Web of Science ®Google Scholar
• Levi ME, Mandava N, Chan LK, et al. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006;8:38-43
   PubMed Web of Science ®Google Scholar
• Dunn JH, Weinberg A, Chan LK, et al. Long-term suppression of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. JAMA Ophthalmol 2013;131:958-60
   PubMed Web of Science ®Google Scholar
• Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2002;46:2373-80
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. for the Maribavir 1263-300 Clinical Study Group. Mirabavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomized trial. Lancet Infect Dis 2011;11:284-92
   PubMed Web of Science ®Google Scholar
• Snydman DR. Why did maribavir fail in stem-cell transplants? Lancet Infect Dis 2011;11:255-7
   PubMed Web of Science ®Google Scholar
• Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol 2011;1:548-54
   PubMed Web of Science ®Google Scholar